Abstract Body

Background

Semaglutide, a GLP-1 receptor agonist, is known to reduce weight and improve cardiometabolic disease outcomes. In a recent randomized, double-blind, placebo-controlled phase 2b clinical trial, we observed significant effects of once-weekly semaglutide over 32 weeks on weight and visceral adiposity in people on stable antiretroviral therapy with HIV-associated lipohypertrophy. Semaglutide has been proposed to have pleiotropic benefits on biological aging; however, whether HIV-associated accelerated epigenetic aging is altered by semaglutide remains unknown.

Methods

We measured longitudinal genome-wide DNA methylation (DNAm) epigenetic profiles in peripheral blood mononuclear cells at baseline and 32 weeks from 84 study participants who were randomized to semaglutide (n=45) or matching placebo (n=39) for 32 weeks. 1st, 2nd, and 3rd generation epigenetic clock algorithms with a principal component-based approach were used to calculate epigenetic ages for participants at entry and 32 weeks. The annual rate of change in each epigenetic clock was calculated for each individual. Student’s t-test was used to compare groups.

Results

Overall, the mean age of participants was 49.2 years (35% female), BMI was 34.3 kg/m2, and CD4+ T cell count was 794 cells/mm3.  Age, sex, BMI, and CD4+ T cell count did not significantly differ between participants randomly assigned to semaglutide versus placebo groups. The mean estimated annual rate of change in epigenetic age over 32 weeks was accelerated for the placebo group for PCHorvath1 (1.9 years), PCHorvath2 (1.9 years), PCHannum (2.3 years), PCPhenoAge (2.7 years), PCGrimAge (1.9 years). In contrast, the mean estimated annual rate of change in the semaglutide arm was: PCHorvath1 (0.25 years), PCHorvath2 (-0.07 years), PCHannum (-0.08 years), PCPhenoAge (-0.29 years), PCGrimAge (-0.58 years), and DunedinPACE (-0.04). The mean annual rate of change was significantly decreased in the semaglutide versus placebo arm for second-generation epigenetic clock PCGrimAge (p=0.02) and third-generation epigenetic clock DunedinPACE (p=0.02). An accelerated PCGrimAge at entry was associated with greater percent BMI change following semaglutide (β=-0.45, p=0.02) when controlling for sex.

Conclusions

Semaglutide attenuated the accelerated epigenetic aging in people with HIV-associated lipohypertrophy. The target population and durability of semaglutide’s effects upon long-term epigenetic aging in PWH warrants further investigation.

Table or Figure